News from FPM
The members of the AMYPAD initiative today announced the start of a novel research initiative between academic and private research partners to investigate the value of β-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia.
Beta-amyloid (β-amyloid) deposition in the brain is one of the neuropathological hallmarks of Alzheimer’s but also occurs in people without the disease. In such cases, the detection of this preclinical phase opens an opportunity for the prevention of the clinical phase of the disease. The recent advent of commercially available β-amyloid PET tracers has opened up new potential for the visualisation of brain β-amyloid and this technology is already being used in hospitals.
Understanding the value of imaging of β-amyloid using PET provides a unique opportunity to achieve 3 major goals: 1) improve the diagnostic workup of people suspected to have AD and their management; 2) understand the natural history of AD in the pre-symptomatic stage; 3) select people for treatment trials aiming at preventing AD by ensuring a more homogeneous and appropriate enrolment. Through engagement with regulators, the AMYPAD consortium will maximize the value of its findings for pharmaceutical companies, healthcare providers, and patients.
AMYPAD will determine in a real-life clinical setting for whom diagnostic β-amyloid imaging is appropriate, when this is best performed and how the resulting information is influencing diagnostic certainty, patient management and ultimately decision trees and cost-effectiveness of dementia care.